{"id":"azd6765-iv","safety":{"commonSideEffects":[{"rate":null,"effect":"Dissociation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AZD6765 blocks NMDA receptors, which are ionotropic glutamate receptors involved in excitatory neurotransmission. By antagonizing these receptors, the drug is thought to rapidly alleviate depressive symptoms through downstream effects on synaptic plasticity and neuronal signaling. This mechanism is similar to ketamine, a known rapid-acting antidepressant, but AZD6765 was designed as a potentially safer alternative with a different pharmacokinetic profile.","oneSentence":"AZD6765 is an NMDA receptor antagonist that modulates glutamatergic neurotransmission to produce rapid-acting antidepressant effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:30:25.391Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder (treatment-resistant depression)"}]},"trialDetails":[{"nctId":"NCT01482221","phase":"PHASE2","title":"A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-12-16","conditions":"Major Depressive Disorder","enrollment":542},{"nctId":"NCT00986479","phase":"PHASE2","title":"This is a Study to Determine the Antidepressant Effects of AZD6765","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-12","conditions":"Treatment Resistant Major Depressive Disorder","enrollment":22},{"nctId":"NCT00963365","phase":"PHASE1","title":"AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Healthy","enrollment":""},{"nctId":"NCT01069822","phase":"PHASE1","title":"A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-02","conditions":"Healthy","enrollment":46},{"nctId":"NCT00781742","phase":"PHASE2","title":"AZD6765 Severe Major Depressive Disorder (MDD) IV","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-10","conditions":"Major Depressive Disorder","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AZD6765 iv","genericName":"AZD6765 iv","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD6765 is an NMDA receptor antagonist that modulates glutamatergic neurotransmission to produce rapid-acting antidepressant effects. Used for Major depressive disorder (treatment-resistant depression).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}